http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4657908-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0d78cd2835221849f6a74e6349185819 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e7c22980d25eb1d159f269bf4aa2c03c |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D251-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D277-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D249-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D249-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D249-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D277-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D251-16 |
| filingDate | 1985-02-12^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1987-04-14^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_711d86e426f1e5f25b8729a3cf73a4d9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_efa84d6e0e44ca08f37f11b90d1485de http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_61ba95d60b056aabce87b61e7e775fcc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3513bc42b89965fcde284dcb14106daa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df88c29702084bf763d37220271115a0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb260ff2bb5e83ac4bf417c0ab2a955f |
| publicationDate | 1987-04-14^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-4657908-A |
| titleOfInvention | Carbonyl derivatives |
| abstract | The invention relates to carbonyl derivatives which are histamine H-2 antagonists and which inhibit gastric acid secretion. According to the invention where is provided a guanidine derivative of the formula I: ##STR1## in which R 1 and R 2 , same or different, are hydrogen or 1-10C alkyl, 3-8C cycloalkyl or 4-14C cycloalkylalkyl, each alkyl, cycloalkyl or cycloalkylalkyl optionally carrying one or more F, Cl or Br atoms, provided that one of R 1 and R 2 is halogen substituted, or R 2 is hydrogen and R 1 is R 5 -E-W in which W is 2-6C alkylene optionally substituted by 1 or 2 1-4C alkyls, E is O, S, SO, SO 2 or NR 6 in which R 6 is H or 1-6C alkyl, R 5 is H or 1-6C alkyl optionally substituted by 1 or 2 1-4C alkyls, or R 5 and R 6 are joined to form a pyrrolidine, piperidine, morpholine, piperazine or N-methylpiperazine ring, or R 2 is H and R 1 is H, 1-10C alkyl, 3-8C cycloalkyl, 4-14C cycloalkylalkyl, 3-6C alkenyl, 3-6C alkynyl, 1-6C alkanoyl, 6-10C aryl, 7-11C aralkyl or 7-11C aroyl; ring X is a heterocyclic ring as defined in the specification; A is phenylene or 5-7C cycloalkylene, or a 1-8C alkylene into which is optionally inserted one or two groups; D is O or S; R 4 is H or 1-6C alkyl; R 3 is H or a variety of radicals described in the specification: and the pharmaceutically-acceptable acid-addition salts thereof. Manufacturing processes and pharmaceutical compositions are also described. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5124459-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022034121-A1 |
| priorityDate | 1981-02-27^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 496 of 496.